

NEOGEN CORP  
Form 8-K  
January 14, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) January 9, 2019**

**NEOGEN CORPORATION**

**(Exact name of registrant as specified in its charter)**

**MICHIGAN**  
**(State or other jurisdiction**

**of incorporation)**

**0-17988**  
**(Commission File Number)**

**38-2367843**  
**(IRS Employer**

**Identification No.)**

**620 Leshar Place Lansing, Michigan**  
**(Address of principal executive offices)**

**48912**  
**(Zip Code)**

**Registrant's telephone number, including area code 517-372-9200**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The Company announced that it had promoted Dr. Jason Lilly to the newly created position of vice president of international business. Lilly joined Neogen in 2005, and has spent the past eight years as Neogen's vice president of corporate development.

In his new role, Lilly will be responsible for maximizing the revenues and profits for Neogen's operations outside of the United States and Canada. Under Lilly's leadership of the corporate development group Neogen completed 20 acquisitions including many international operations that are now his responsibility.

Lilly is based at Neogen's corporate headquarters in Lansing, Mich., and reports directly to CEO John Adent. The company has initiated a candidate search to replace Lilly in its corporate development group.

A copy of the press release issued by the Registrant to announce the above is attached to this Current Report as Exhibit 99. This press release is being furnished to, as opposed to filed with, the Securities and Exchange Commission.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

Exhibit 99.1 Press Release issued by the Registrant on January 9, 2019

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGEN CORPORATION  
(Registrant)

Date: January 14, 2019

/s/ Steven J. Quinlan  
Steven J. Quinlan  
Vice President & CFO